Cullinan Therapeutics (CGEM) vs Ginkgo Bioworks (DNA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cullinan Therapeutics (CGEM) has outperformed Ginkgo Bioworks (DNA) over the past year, gaining 165.4% versus a loss of 22.6%. Over five years, CGEM leads with a -37.5% price change compared with -97.6% for DNA. Cullinan Therapeutics is the larger company by market cap ($960.6 million vs $772.4 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGEM | DNA |
|---|---|---|
| Share price | $15.63 | $11.47 |
| Market cap | $960.59M | $772.39M |
| 1-day change | -3.82% | -7.57% |
| YTD return | +51.01% | +38.03% |
| 1-year return | +165.37% | -22.60% |
| 5-year return | -37.48% | -97.59% |
| EPS (TTM) | $-3.11 | $-5.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $23.19 | $18.22 |
| 52-week low | $5.85 | $5.37 |
| Distance from 52-week high | -32.60% | -37.05% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +114.01% | -38.97% |
| Average volume | 868.12K | 1.69M |
| Shares outstanding | 61.46M | 55.38M |
| Employees | 109 | 485 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CGEM has outperformed DNA by 188.0 percentage points over the past year.
About Cullinan Therapeutics
CGEM stock →Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome.
Healthcare · Biotechnology · 109 employees
About Ginkgo Bioworks
DNA stock →Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments.
Healthcare · Biotechnology · 485 employees
CGEM vs DNA FAQ
Which is bigger, Cullinan Therapeutics or Ginkgo Bioworks?
Cullinan Therapeutics (CGEM) is larger, with a market capitalization of $960.59M compared with $772.39M for Ginkgo Bioworks (DNA).
Which stock has performed better over the past year, CGEM or DNA?
CGEM returned +165.37% over the past 12 months, compared with -22.60% for DNA (price return, excluding dividends). Past performance does not predict future results.
Are Cullinan Therapeutics and Ginkgo Bioworks in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.